Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Provectus Biopharmaceuticals, Inc.

http://www.provectusbio.com/

Latest From Provectus Biopharmaceuticals, Inc.

AnGes To Withdraw, Refile HGF Gene Therapy In Japan

If finally fully approved in its first indication, the HGF gene therapy could become a first-in-class therapy for PAD - but only after years of challenges in clinical trials.

Japan Gene Therapy

Deal Watch: Lilly Partners With OpenAI On Drug-Resistant Pathogens

Plus transactions involving ANI/Alimera, Gilead/ashibio, Sanofi/Belharra and more.

Deal Watch Business Strategies

Otsuka Pays Price As AVP-786 Dropped For Alzheimer's Agitation

Otsuka has now formally decided to terminate the development of AVP-786 for Alzheimer's agitation, for which it is set to book another JPY100bn loss this year, and marking a major setback for an asset that was a key attraction in a previous large acquisition.

Research & Development Neurology

Deal Watch: AbbVie Pursues Novel Neuropsychiatric Drug Class With Gilgamesh

Plus transactions involving Sanofi/Fulcrum, Reneo/OnKure, Lilly/Mitsubishi Tanabe, Lantern/Oregon, Zydus/Eiger and more.

Deal Watch Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Medical Devices
    • Laser
  • Other Names / Subsidiaries
    • Provectus Biopharmaceuticals Australia Pty Ltd.
    • Provectus Pharmaceuticals, Inc.
UsernamePublicRestriction

Register